Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$9.66 USD
-0.49 (-4.83%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $9.70 +0.04 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Iovance Biotherapeutics, Inc. [IOVA]
Reports for Purchase
Showing records 1 - 20 ( 193 total )
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; AMTAGVI Shows Early Success as ex-U.S. Regulatory Efforts Pick Up
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lifileucel MAA Submitted to EMA; Additional Ex-U.S. Regulatory Submissions Remain on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pair of ASCO Presentations Provide a Window Into a Maturing TIL-Based Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lifileucel Impresses at ASCO; TIL Therapy Exhibits Promise in CKI Naive Advanced Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Abstract Underscores Lifileucel''s Potential As an Early Line Therapy in Advanced Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Robust AMTAGVI Enrollment Kicks Off 2024; Global Markets Come Into View
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let the Good News Flow; FDA Lifts Partial Hold on IOV-LUN-202
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; AMTAGVI Takes Off as TIL Portoflio Readies Next Runway
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J